↓ Skip to main content

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML

Overview of attention for article published in Blood, June 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news
1 news outlet
twitter
9 X users
patent
1 patent

Citations

dimensions_citation
128 Dimensions

Readers on

mendeley
100 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML
Published in
Blood, June 2018
DOI 10.1182/blood-2018-01-821629
Pubmed ID
Authors

Jorge E Cortes, Martin S Tallman, Gary J Schiller, Denise Trone, Guy Gammon, Stuart L Goldberg, Alexander E Perl, Jean-Pierre Marie, Giovanni Martinelli, Hagop M Kantarjian, Mark J Levis

X Demographics

X Demographics

The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 100 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 100 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 19 19%
Student > Bachelor 12 12%
Other 9 9%
Student > Ph. D. Student 9 9%
Student > Master 8 8%
Other 18 18%
Unknown 25 25%
Readers by discipline Count As %
Medicine and Dentistry 33 33%
Biochemistry, Genetics and Molecular Biology 16 16%
Pharmacology, Toxicology and Pharmaceutical Science 8 8%
Nursing and Health Professions 4 4%
Unspecified 3 3%
Other 10 10%
Unknown 26 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 February 2024.
All research outputs
#2,053,767
of 25,508,813 outputs
Outputs from Blood
#2,037
of 33,361 outputs
Outputs of similar age
#41,931
of 342,849 outputs
Outputs of similar age from Blood
#57
of 226 outputs
Altmetric has tracked 25,508,813 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 33,361 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,849 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 226 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.